바로가기 메뉴

단축키 목록

맨 위로

현재 페이지 위치 : 삼성유전체연구소 > ABOUT US > Institute Overview

Institute Overview

 
Samsung Genome Institute was launched in March 2013 to develop a comprehensive system for the implementation of precision cancer medicine based on genome sequencing and analysis.In order to provide personalized treatment to cancer patients, various kinds of genome research are performed in collaboration with multiple specialists and clinicians in the fields of cancer genomics, bioinformatics and functional genomics.

 

Samsung Genome Institute

· Operates the highest global standards level of genome analysis infrastructure
· Establishes a next-generation
· Endeavors to improve the quality of life of patients improve treatment performance and reduce medical
  costs by establishing world-class genome-based personalized treatment system through securing global
  research capabilities based on the development of core genome technology

 

Clinical Sequencing Platform

· 4 Illumina sequencers (3 HiSeqs and 1 MiSeq) operated by 7 trained specialists
· 5,000 cases/year undergo CancerSCAN™ using Agilent Bravo automated library preparation system
· Quality management of clinical sequencing workflow by using in-house optimized LIMS(Laboratory
  Information Management System), QA/QC workflow from sample preparation to BI,
  and regular proficiency tests from CAP(College of american Pathologists) and EMQN(The European
  Molecular Genetics Quality Network)

· Single-cell genome analysis platform comprising C1 (Fluidigm), Chromium (10x Genomics),
   and in-house Drop-seq

· Functional Genomics high-throughput screening platform with liquid handler